Business Trends– category –
-
uOttawa Neuro-Therapy: EV-Delivery and Autophagy-Tagging Strategy
University of Ottawa Canada Overview Researchers at the University of Ottawa have developed a dual-action strategy using extracellular vesicles and engineered antibodies to clear pathological proteins linked to Alzheimer’s, ALS, and deme... -
VERAXA Biotech: BiTAC-ADC in vivo proof-of-concept data 2026
Nasdaq USA Overview VERAXA Biotech presented in vivo data demonstrating that its BiTAC-ADC technology selectively triggers tumor-specific responses and significant tumor volume reduction. The platform utilizes a dual-targeting prodrug sy... -
ConsiGma CDC Flex: Hovione’s 2026 US continuous tableting launch
Chemistry Today Portugal Overview Hovione has launched the world's first next-generation ConsiGma® CDC Flex continuous tableting system at its U.S. facility in New Jersey. This investment establishes a seamless continuous flow pathway fr... -
Ac-225: NorthStar Medical Technologies production and FDA specs
The Pharma Letter USA Overview NorthStar Medical Technologies became the industry's first to commercially produce carrier-free Actinium-225 (Ac-225) using electron accelerator technology in January 2026. In April of the same year, the FD... -
Datroway: Daiichi Sankyo and AstraZeneca China approval 2026
Daiichi Sankyo Japan Overview Datroway® (datopotamab deruxtecan), a TROP2-directed DXd antibody-drug conjugate (ADC) co-developed by Daiichi Sankyo and AstraZeneca, has been approved in China for adult patients with unresectable or metas... -
Oncopeptides PDC: Blood-brain barrier specs for brain tumors
Oncopeptides AB (publ) Sweden Overview Oncopeptides AB confirmed that its peptide-drug conjugate (PDC) platform successfully penetrates the blood-brain barrier (BBB) and delivers cytotoxic payloads directly into brain tumor cells, based ... -
mRNA-LNP delivery explained: Georgia Tech’s 2026 oral vaccine
News-Medical USA Overview Researchers at Georgia Tech and Emory University have developed a groundbreaking lipid nanoparticle (LNP) formulation that enables precise targeting of specific regions within the gastrointestinal (GI) tract. Th... -
Oral GLP-1 Agonists: Weight loss and HbA1c efficacy explained
Apps Script USA Overview Clinical data reviews have confirmed the effectiveness of oral GLP-1 receptor agonists in significantly lowering HbA1c levels and inducing modest weight loss. Crucially, strict adherence to pre-dosing fasting pro... -
Olpasiran: Novartis’ Phase 2b siRNA Lp(a) reduction results
Biomedical Science Letters South Korea Overview Novartis' investigational siRNA therapeutic, olpasiran, demonstrated remarkable efficacy in the Phase 2b OCEAN(a)-DOSE trial, reducing lipoprotein(a) (Lp(a)) levels by over 95% at high dose... -
Exosome Delivery: 6-fold Paclitaxel concentration for GBM specs
Zuglueducation.com Unknown Overview Exosome-based drug delivery systems have achieved breakthrough results in a Phase I/II clinical trial for glioblastoma multiforme (GBM). Paclitaxel-loaded exosomes, derived from patient mesenchymal ste...
